RNS Number : 2665Y
Alliance Pharma PLC
29 July 2024
 

For immediate release

29 July 2024

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")


Result of AGM

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, at its Annual General Meeting held earlier today, all the resolutions except resolutions 16 and 17, as set out in the Notice of Meeting, were duly passed on a poll.

The number of the Group's shares in issue as at the date of the meeting was 540,565,539 ordinary shares of 1p each*.

The votes were as follows:

 

RESOLUTION

VOTES FOR

%

VOTES AGAINST

%

VOTES WITHHELD

1

Report and Accounts

190,733,158

99.99

14,451

0.01

12,870

2

Approve Remuneration Report

118,424,151

62.09

72,319,389

37.91

16,939

3

Elect C. Pane

167,821,883

99.34

1,108,987

0.66

21,829,609

4

Elect R. McKenzie

190,719,135

99.98

28,979

0.02

12,365

5

Elect EL. Sjostedt

190,672,019

99.96

76,095

0.040

12,365

6

Elect N. Sedgwick

190,708,640

99.98

38,979

0.020

12,860

7

Re-elect A. Franklin

190,546,663

99.89

201,451

0.11

12,365

8

Re-elect J. Heper (Withdrawn)

-

-

-

-

-

9

Re-elect R. Jones

119,208,411

62.55

71,381,969

37.45

170,099

10

Re-elect K. Neirynck

190,554,413

99.98

36,462

0.02

169,604

11

Re-elect M. Sutherland

119,879,952

62.90

70,710,923

37.10

169,604

12

Appointment of Auditor

190,656,799

99.95

90,085

0.05

13,595

13

Remuneration of Auditor

190,715,105

99.98

32,274

0.02

13,100

14

Allot shares - general

119,812,913

62.81

70,933,841

37.19

13,725

15

Allot shares - additional

120,008,767

62.92

70,735,963

37.08

15,749

16

Disapply pre-emption rights - general

119,970,667

62.90

70,776,712

37.10

13,100

17

Disapply pre-emption rights - additional

119,912,206

62.86

70,835,173

37.14

13,100

The Board notes the votes against Resolutions 2, 9, 11, 14, 15, 16 and 17 and will consult with shareholders to understand their views and publish the results of that consultation in due course.

Chris Chrysanthou
Group General Counsel & Company Secretary
29 July 2024

*Each share carries one vote and a 'vote withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes for and against the resolution. Any proxy appointments which gave discretion to the Chairman have been included in the 'votes for' total.

 

 

 

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com




Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills


alliancepharma@buchanan.uk.com




Deutsche Numis (Nominated Adviser and Joint Broker)

+ 44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Sher Shah




Investec Bank plc (Joint Broker)

+ 44 (0)20 7597 5970

Patrick Robb / Ben Lawrence / Maria Gomez de Olea


 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 290 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSESFIUELSEFW